Literature DB >> 17609274

Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand.

Brian J Willett1, Elizabeth L McMonagle, Nicola Logan, O Brad Spiller, Pascal Schneider, Margaret J Hosie.   

Abstract

The feline immunodeficiency virus (FIV) targets activated CD4-positive helper T cells preferentially, inducing an AIDS-like immunodeficiency in its natural host species, the domestic cat. The primary receptor for FIV is CD134, a member of the tumor necrosis factor receptor superfamily, and all primary viral strains tested to date use CD134 for infection. We examined the expression of CD134 in the cat using a novel anti-feline CD134 monoclonal antibody (MAb), 7D6, and showed that as in rats and humans, CD134 expression is restricted tightly to CD4+, and not CD8+, T cells, consistent with the selective targeting of these cells by FIV. However, FIV is also macrophage tropic, and in chronic infection the viral tropism broadens to include B cells and CD8+ T cells. Using 7D6, we revealed CD134 expression on a B220-positive (B-cell) population and on cultured macrophages but not peripheral blood monocytes. Moreover, macrophage CD134 expression and FIV infection were enhanced by activation in response to bacterial lipopolysaccharide. Consistent with CD134 expression on human and murine T cells, feline CD134 was abundant on mitogen-stimulated CD4+ T cells, with weaker expression on CD8+ T cells, concordant with the expansion of FIV into CD8+ T cells with progression of the infection. The interaction between FIV and CD134 was probed using MAb 7D6 and soluble CD134 ligand (CD134L), revealing strain-specific differences in sensitivity to both 7D6 and CD134L. Infection with isolates such as PPR and B2542 was inhibited well by both 7D6 and CD134L, suggesting a lower affinity of interaction. In contrast, GL8, CPG, and NCSU were relatively refractory to inhibition by both 7D6 and CD134L and, accordingly, may have a higher-affinity interaction with CD134, permitting infection of cells where CD134 levels are limiting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609274      PMCID: PMC2045395          DOI: 10.1128/JVI.01020-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Functional characterization of OX40 expressed on human CD8+ T cells.

Authors:  Tomoko Fujita; Naoya Ukyo; Toshiyuki Hori; Takashi Uchiyama
Journal:  Immunol Lett       Date:  2006-04-25       Impact factor: 3.685

2.  The crystal structure of the costimulatory OX40-OX40L complex.

Authors:  Deanne M Compaan; Sarah G Hymowitz
Journal:  Structure       Date:  2006-08       Impact factor: 5.006

3.  Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus.

Authors:  Thomas W Vahlenkamp; Anthony De Ronde; Nancy N M P Schuurman; Arno L W van Vliet; Judith van Drunen; Marian C Horzinek; Herman F Egberink
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

4.  Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors.

Authors:  Anjali Joshi; Himanshu Garg; Mary B Tompkins; Wayne A Tompkins
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Differential cell tropism of feline immunodeficiency virus molecular clones in vivo.

Authors:  G A Dean; S Himathongkham; E E Sparger
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.

Authors:  Claudia Bossen; Karine Ingold; Aubry Tardivel; Jean-Luc Bodmer; Olivier Gaide; Sylvie Hertig; Christine Ambrose; Jürg Tschopp; Pascal Schneider
Journal:  J Biol Chem       Date:  2006-03-17       Impact factor: 5.157

7.  Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus.

Authors:  T Miyazawa; T Furuya; S Itagaki; Y Tohya; E Takahashi; T Mikami
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding.

Authors:  O B Spiller; L Mark; C E Blue; D G Proctor; J A Aitken; A M Blom; D J Blackbourn
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Francesca Bonci; Mauro Pistello; Margaret J Hosie
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

10.  Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Susan Ridha; Margaret J Hosie
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more
  13 in total

Review 1.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

Review 2.  Transmission, Evolution, and Endogenization: Lessons Learned from Recent Retroviral Invasions.

Authors:  Alex D Greenwood; Yasuko Ishida; Sean P O'Brien; Alfred L Roca; Maribeth V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2017-12-13       Impact factor: 11.056

3.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

4.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

5.  Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes.

Authors:  Samantha J McDonnel; Ellen E Sparger; Paul A Luciw; Brian G Murphy
Journal:  Virus Res       Date:  2012-10-13       Impact factor: 3.303

Review 6.  The virus-receptor interaction in the replication of feline immunodeficiency virus (FIV).

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Curr Opin Virol       Date:  2013-08-28       Impact factor: 7.090

7.  Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells.

Authors:  Chi Ngai Chan; Elizabeth L McMonagle; Margaret J Hosie; Brian J Willett
Journal:  Virus Res       Date:  2012-11-28       Impact factor: 3.303

8.  Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth McMonagle; Mariana Varela; Margaret J Hosie
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

9.  A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2008-08-22       Impact factor: 4.602

10.  Genetically divergent strains of feline immunodeficiency virus from the domestic cat (Felis catus) and the African lion (Panthera leo) share usage of CD134 and CXCR4 as entry receptors.

Authors:  William A McEwan; Elizabeth L McMonagle; Nicola Logan; Rodrigo C Serra; Pieter Kat; Sue Vandewoude; Margaret J Hosie; Brian J Willett
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.